Q-omics provides the consensus-scored MFSD5 profile across patient tissues and cancer cell-line models. MFSD5 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, MFSD5 is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, MFSD5 RNA expression shows 18,687 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LUAD, KIRP, and ACC as cancer lineages where MFSD5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MFSD5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MFSD5 survival associations across molecular data types. MFSD5 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MFSD5 RNA expression–survival associations across cancer types. High MFSD5 expression shows unfavorable associations in LUAD, LIHC, MESO, KIRP, LGG and UVM. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for MFSD5 RNA expression.
This table summarizes MFSD5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MFSD5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MFSD5 shows higher tumor expression in KIRP, KIRC, LIHC, BLCA, BRCA and LUSC. The KIRP box plot shows higher MFSD5 RNA expression in tumor versus normal tissue (log2 FC = +1.303, t-test p < 0.001).
This table shows molecular features associated with MFSD5 in patient tissues and cancer cell lines. In patient samples, MFSD5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MFSD5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and UPPER_AERODIGESTIVE_TRACT.
